PURA syndrome is a recently described developmental encephalopathy presenting with neonatal hypotonia, feeding difficulties, global developmental delay, severe intellectual disability, and frequent apnea and epilepsy. We describe 18 new individuals with heterozygous sequence variations in PURA. A neuromotor disorder starting with neonatal hyptonia, but ultimately allowing delayed progression to walking, was present in nearly all individuals. Congenital apnea was present in 56% during infancy, but all cases in this cohort resolved during the first year of life. Feeding difficulties were frequently reported, with gastrostomy tube placement required in 28%. Epilepsy was present in 50% of the subjects, including infantile spasms and Lennox-Gastaut syndrome. Skeletal complications were found in 39%. Disorders of gastrointestinal motility and nystagmus were also recurrent features. Autism was diagnosed in one individual, potentially expanding the neurodevelopmental phenotype associated with this syndrome. However, we did not find 56 |
additional PURA sequence variations in a cohort of 120 subjects with autism. We also present the first neuropathologic studies of PURA syndrome, and describe chronic inflammatory changes around the arterioles within the deep white matter. We did not find significant correlations between mutational class and severity, nor between location of the sequence variation in PUR repeat domains. Further studies are required in larger cohorts of subjects with PURA syndrome to clarify these genotype-phenotype associations.
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| INTRODUCTION
PURA syndrome (OMIM #616158) is a recently described disorder characterized by early hypotonia and global developmental delay, with most affected individuals having disability in expressive language development. Many individuals, but not all, have epilepsy and in some cases the seizures may be intractable. Persons affected with PURA haploinsufficiency were first identified with deletions on 5q31.3 (Brown et al., 2013) . Diagnostic whole exome sequencing allowed the subsequent identification of pathogenic sequence variations in the gene (Hunt et al., 2014; Lalani et al., 2014; Tanaka et al., 2015) . While there was early suggestion that sequence variations disrupting the PUR repeat II and PUR repeat III regions may correlate with clinical severity, (Hunt et al., 2014) there is much regarding the phenotypic spectrum associated with PURA syndrome that is not yet understood.
We report 18 new individuals with de novo pathogenic sequence variations in PURA, the largest clinical series described to date. We detail the developmental history, and elaborate on the neurodevelopmental phenotype to include a less severely affected individual with a diagnosis of autism. We also detail the nature and incidence of medical complications, and describe the first neuropathological examination of an individual with PURA syndrome. Finally, we make several recommendations for the medical management of individuals with this disorder. 
| Whole exome sequencing
Subject DB13-043 and both parents had research whole exome sequencing performed on saliva-derived DNA, using the Agilent SureSelect 50 Mb whole exome capture kit. Paired end 100 bp reads were generated on an Illumina HiSeq2500 sequencer at the University of 
| PURA Sanger sequencing
Subjects (n = 120) with autism underwent sequencing of saliva-derived DNA for the single exon of PURA (NM_005859) using Sanger methods.
Primer sequences are given in Supplemental Table S1 . 
| Autism assessments
Individuals with autism were diagnosed based upon the Autism Diagnostic Observation Schedule (ADOS), and the Autism Diagnostic Interview, Revised (ADI-R).
| Neuropathologic studies
Gross and microscopic examination of the formalin-fixed brain of subject DB16-016 was performed using standard methods.
| 57 2.6 | Statistical analyses All statistical analyses were performed using R version 3.2.0 (cranproject.org). For genotype-phenotype correlations, we established a clinical severity index comprised of the outcomes epilepsy, apnea, G-tube placement, skeletal abnormalities, and nonambulation. A higher index score indicated greater severity (values range 0-5). We assigned a value of "severe outcome" to those scoring ≥3 on the severity index, and then tested for correlations with genotype.
| RESULTS
We report a total of 18 new individuals with PURA syndrome, 10 males and 8 females. The mean age at the time of study was 7.4 years, with the youngest individual 11 months and the oldest 27 years.
Prior to identification of PURA mutations, subjects had a range of previous diagnoses, including autism, cerebral palsy, "Rett-like disorder," pervasive developmental disorder, and "likely mitochondrial disease."
| Whole exome sequencing
A de novo c.596G>C (p.Arg199Pro) sequence variation in PURA in subject DB13-043 was identified using research whole exome sequencing at the University of Rochester Medical Center. This PURA mutation was previously described (Lalani et al., 2014) confirming the pathogenicity of this sequence variation. The remainder of the subjects reported here had their sequence variations in PURA identified using clinical whole exome sequencing, illustrating the value of this diagnostic technology (Yang et al., 2014) . The genotype results of the subjects reported in this study are detailed in Table 1 . We observed five missense, four nonsense, seven frameshift indel, and two nonframeshift indel mutations. Subject DB15-021 had both a missense and a nonsense mutation in PURA, but for the purposes of genotype-phenotype correlations the nonsense mutation was re- 3.2 | Neonatal hypotonia leading to consistent neuromotor phenotype Our subjects nearly universally had neonatal onset hypotonia, often with difficulties tolerating oral feeding in the newborn period resulting in prolonged hospitalizations. Gross motor development in general was delayed, but of the subjects older than 5 years of age at the time of study (n = 9) all were ambulatory. Gait was notable in many subjects for increased tone in the lower extremities, ataxia in others, and a diagnosis of "cerebral palsy" was frequently applied. In other published cohorts, motor development was severely impaired in some individuals, with many never attaining independent ambulation (Hunt et al., 2014; Lalani et al., 2014; Tanaka et al., 2015) .
3.3 | Common language impairment, intellectual disability, and autism spectrum disorder (ASD) Nearly all subjects in this series had absent verbal language, consistent with previous reports in PURA syndrome (Hunt et al., 2014; Lalani et al., 2014; Tanaka et al., 2015) . One exception was subject DB15-030, a 15-year-old boy with a missense PURA p.Arg140Pro sequence variation and higher functioning language skills. This subject received a clinical diagnosis of autism at age 11 years. This individual was ambulatory and had seizures controlled on a single medication, suggesting that some missense PURA sequence variations may be associated with a milder phenotype. Due to this diagnosis of autism, we investigated a cohort of 120 individuals with ASD for variations in PURA. As we did not find any pathogenic sequence variations, it is possible the association of autism with sequence variation in PURA is only coincidental (Figure 2 ).
| Variability of epilepsy
Nine (50%) out of 18 individuals in this series had a diagnosis of epilepsy, with some having recognizable electroclinical syndromes such as infantile spasms (2 subjects) and Lennox-Gastaut syndrome (1 subjects).
Several individuals reported previously also had diagnoses of LennoxGastaut syndrome or other intractable seizure types (Lalani et al., 2014) .
Two new subjects in this report (DB15-033 and DB16-017) had infantile spasms. Subject DB15-033 had onset of spasms at 11 months which responded to vigabatrin. This individual had a p.Leu168CysFS* mutation in the PUR-II domain of PURA. Subject DB16-017 had onset of spasms at 1 year, which initially did not respond to vigabatrin but spasms subsequently stopped and the EEG normalized after two doses of adrenocorticotropic hormone. This individual had a p.Arg150Profs*48 frameshift mutation in the PUR-II domain of PURA. The previously reported individual in the literature with infantile spasms had a p.Phe233del mutation in the PUR-III domain (Hunt et al., 2014) .
Two individuals in our series had epilepsy presenting later in childhood, and one individual (DB16-012) had neonatal seizures that remitted, with recurrence of epilepsy at age 6 years. Subject DB16-016 did not have seizure onset until 16 years of age, but her epilepsy became intractable, requiring several anti-seizure medications for treatment and was associated with loss of cognitive and motor skills.
Five (28%) individuals in our series had exaggerated startle response to stimuli, but without epileptiform correlate on EEG. This was a finding reported in several previously published individuals, and appears to be a neuromotor behavior recurrent in PURA syndrome. Nystagmus was present in 5 (28%) of our subjects, was horizontal and was associated with poor visual attentiveness. Details of neurodevelopment, epilepsy, and other neurologic symptoms are provided in Table 1 .
| MRI findings consistent with a generalized disorder of white matter maturation
Brain MRIs from 12 of 18 subjects were available for review. No malformations of cortical or subcortical development were observed, 3.6 | Congenital apnea resolving in the first year of life
Congenital apnea was a frequent finding in our cohort, with 10 (56%) individuals with congenital apnea complicating their neonatal course.
In most cases, the neonatal central apnea improved by the first year of life. There were no reports of other breathing dysrythmias later in life, and there was no report of pulmonary complications. Several patients developed obstructive apnea later in life. Subject DB16-016 died after a prolonged respiratory illness, but the mortality was attributed more to generalized neurologic decline, and not to a specific disorder of breathing regulation.
| Frequent skeletal complications
Skeletal complications occurred in seven (39%) of the individuals in our cohort, with three subjects developing scoliosis, two with hip dysplasia or hip dislocation, and two with osteopenia or osteoporosis. As these complications tended to be diagnosed as individuals grew older, it is possible the true prevalence is higher as ten of our subjects were 5 years old or younger.
| Frequent abnormalities of gastric motility
Six (33%) individuals had gastroesophageal reflux disease, with four requiring fundoplication. Five (28%) individuals had gastric feeding tubes placed, and these were usually placed early in infancy as a consequence of poor neonatal oral feeding. Nine (50%) individuals had constipation, which usually responded to oral medications. 3 Representative brain MRI findings in individuals with PURA syndrome. Subject DB13-043, a 5-year-old girl with hypotonia and epilepsy, had thinning of the corpus callosum (a) and of the subcortical white matter with increased extra-axial fluid spaces (b). Subject DB15-027, a 4-year-old boy with hypotonia and cortical visual impairment, had mildly increased extra-axial fluid in the posterior fossa (c) and thinning of the cerebral white matter (d). Subjects DB15-021 (e-g) and DB15-033 (h-j) had subarachnoid cysts (arrowhead). Subject DB16-002 had thickening of the corpus callosum and cerebellar tonsilar ectopia (asterix) develop over scans at ages 2 years (k), 6 years (l), and 9 years (m). Coronal T2 FLAIR image from subject DB16-016 at age 20 years showing mild dilation of the lateral ventricles and increased signal in the subcortical white matter (n). Gross brain specimen of subject DB16-016 confirming ventricular and white matter findings seen on neuroimaging (o) [Color figure can be viewed at wileyonlinelibrary.com] Single incidences of other malformations occurred in our cohort, including one case of cardiac ventricular septal defect not requiring surgery, two occurrences of patent foramen ovale. Other nonrecurrent medical complications included hypothyroidism (n = 1), eosinophilic esophagitis (n = 1), renal stones (n = 1), anemia (n = 2), neutropenia (n = 1), and short stature (n = 1). The occurrences of anemia, neutropenia, and renal stones may have been complications of antiseizure medications. The medical co-morbidities observed in our cohort with PURA syndrome are summarized in Table 2. 3.9 | Neuropathologic examination identifies chronic inflammatory changes in the arterioles of the deep white matter Subject DB16-016 died at the age of 27 years after a prolonged respiratory illness. Gross examination found a normal brain weight, no major malformations, and confirmed mild ventricular enlargement seen on prior neuroimaging (Figures 3n and 3o ). Microscopic examination identified perivascular changes in the arterioles of the deep white matter consistent with chronic inflammation (Figure 4 ).
Trichrome, Congo Red, and Periodic Acid-Schiff stains were normal (Supplementary Figure S1 ).
| Recurrent PURA mutations demonstrate clinical variability
We observed several mutations in PURA that were recurrent in our series, and/or were reported previously in the literature. Two individuals in this report (subjects DB15-027 and DB16-032) had the p.Phe233del sequence variation. Subject DB16-032 had seizure onset during the first two weeks of life and central apnea, but the other did not have epilepsy or a history of apnea. Interestingly, a previously reported patient with the p.Phe233del mutation had infantile spasms with progressive epilepsy and central apnea (Hunt et al., 2014) .
Another previously reported patient with this sequence variation did not have any seizures or apnea at 6 months of age (Tanaka et al., 2015) . Subject DB15-027 had cortical visual impairment, and both previously reported patients with this sequence variation were noted to have eye abnormalities as well (Hunt et al., 2014; Tanaka et al., 2015) .
We identified subject DB13-043 with the missense p.Arg199Pro mutation, which had been reported previously in the literature (Lalani et al., 2014) . While both individuals had intractable epilepsy, the previously reported patient was diagnosed with Lennox-Gastaut syndrome. Both subjects had nystagmus and neither had any skeletal abnormalities.
| Genotype-phenotype correlations
We established a clinical severity index comprised of the outcomes epilepsy, apnea, G-tube placement, skeletal abnormalities, and nonambulation after age 5 years. A higher index score indicated greater severity. We then tested for correlations with genotype. When we grouped likely haploinsufficient variations (i.e., nonsense and frameshift indels) and compared to variations that perhaps might not lead to haploinsufficiency (i.e., missense and nonframeshift indels), we did not find significant differences in clinical severity. There was also no (Mowat, Wilson, & Goossens, 2003) , and Pitt-Hopkins syndrome (Amiel et al., 2007) . Like those disorders, early hypotonia, severe language impairment, variable epilepsy severity, and abnormal patterns of movement are common features. We did not find consistent dysmorphologic features in our cohort, but rather observed that the facies in infancy in PURA syndrome is notable for sequelae of hypotonia which improved as the child matured.
Global developmental delay and intellectual disability with an absence of verbal language development are also common themes in developmental encephalopathies caused by haploinsufficiency of transcription factors important during early brain development.
However, there can be considerable variability, as evidenced by the individual reported here with a missense PURA mutation with verbal language development and a diagnosis of autism. All other patients in our cohort had severe intellectual disability. This observation has been made as well in FOXG1 syndrome, where most affected individuals have severe cognitive impairment, precluding a diagnosis of autism, but only recently have more mildly affected individuals been identified who received a prior diagnosis of autism (McMahon et al., 2015) . We were, therefore, interested in identifying PURA mutations in our cohort of individuals with autism spectrum disorders. While we were not successful, the presence of an individual in our PURA syndrome cohort with a diagnosis of autism suggests that the neurodevelopmental phenotype associated with this syndrome may be broader than was first suspected. A larger sample size may be needed to test the true prevalence of PURA mutations among individuals diagnosed with autism spectrum disorders.
We observed variability in epilepsy type and severity in our cohort, with half of our subjects having a diagnosis of epilepsy. Some individuals had a diagnosis of electroclinical syndromes (infantile spasms and Lennox-Gastaut syndrome), while others developed seizures later in childhood. In some cases, the seizures were intractable, even though their onset was in the second decade of life. We did not appreciate an overall correlation between sequence variation type or location and epilepsy, but this observation must be treated with caution since the number of patients overall described with PURA syndrome is still small. The variability of both epilepsy type and severity, however, is typical of this class of developmental brain disorders due to sequence variations in transcription factors.
Brain MRI findings in our cohort were consistent with those previously described (Hunt et al., 2014; Lalani et al., 2014; Tanaka et al., 2015) , and included frequent dysmaturation of the cortical white matter. Two of our subjects had arachnoid cysts, and one had the onset of cerebellar tonsillar ectopia. However, we do not hold any of those findings to be clinically significant, and certainly not specific to PURA syndrome.
Congenital and central apnea was present in 55% of our subjects in this cohort. Neonatal apnea was also described previously in infants with PURA syndrome (Hunt et al., 2014; Lalani et al., 2014; Tanaka et al., 2015) , indicating this may be a helpful diagnostic feature if present in an infant with severe hypotonia and feeding difficulties.
Abnormalities in breathing rhythm are also found in MECP2 syndrome (Ramirez, Ward, & Neul, 2013) as well as Pitt-Hopkins syndrome (Zweier et al., 2008) , suggesting that the molecular function of PURA may be similarly involved in automatic regulation of breathing by the brainstem. In most of the subjects described in this report, apnea occurred in the neonatal period, could persist throughout infancy, but generally improved over time. We found no correlation between sequence variation type or location and the occurrence of apnea in our subjects.
Skeletal complications were also present in more than a third of the individuals in this series, and ranged from osteoporosis to hip dysplasia and, most frequently, scoliosis. While osteopenia was Gastric motility disorder (GERD 33%; constipation 50%) GERD may be severe enough to require fundoplication. Many individuals also have difficulties with oral feeding due to hypotonia, and may require gastrostomy tube placement. Constipation may require stool softeners and/or motility agents.
Nystagmus (28%) Referral to pediatric ophthalmologist for assessment and management.
